SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2.

Signal Transduct Target Ther · 2022 · PMC8727475 · PMID 34987150

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a weak trendno p-value reported

Another marketed mAb, Regdanvimab, has a weak trend of decreased binding affinity but without significance to either WT or Delta.

also in 1,404 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.